Detect Parkinson and track severity
- Trial ID
- NCT07392411
- Official Title
- Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
- Goal
- Detect Parkinson and track severity
- Status
- RECRUITING
- Sponsor
- Beijing Tiantan Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 720 participants
- Conditions
- Parkinson's Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy, Healthy Control
- Interventions
- video recording
Plain-Language Summary
Researchers are using AI to detect and quantify subtle changes in facial expression and speech that could become digital biomarkers to help detect Parkinson's disease, distinguish Parkinson-plus conditions like PSP and MSA, and track disease severity over time. They record short videos and audio of your face and voice, then use algorithms to measure things like reduced facial expressivity, slowed or softer speech, altered pitch and timing, and other motor-related voice signals, all noninvasively and without changing your medications. The study is looking for adults 18 to 75 with diagnosed PD, PSP, or MSA, plus healthy controls who can consent and tolerate recording; people with significant cognitive impairment (MMSE ≤ 24), major brain injury or surgery, severe dyskinesia that prevents reliable recording, and other listed exclusions are not eligible.
Locations
- 首都医科大学附属北京天坛医院, Beijing, Beijing Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying video recording. Researchers are using AI to detect and quantify subtle changes in facial expression and speech that could become digital biomarkers to help detect Parkinson's disease, distinguish Parkinson-plus conditions like PSP and MSA, and track disease severity over time. They record short videos and audio of your face and voice, then use algorithms to measure things like reduced facial expressivity, slowed or softer speech, altered pitch and timing, and other motor-related voice signals, all noninvasively and without changing your medications. The study is looking for adults 18 to 75 with diagnosed PD, PSP, or MSA, plus healthy controls who can consent and tolerate recording; people with significant cognitive impairment (MMSE ≤ 24), major brain injury or surgery, severe dyskinesia that prevents reliable recording, and other listed exclusions are not eligible.
- Who can participate?
- Participants must be between 15 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 5 months.